Search hospitals > Missouri > Springfield

Mercy Hospital Springfield

Claim this profile
Springfield, Missouri 65804
Global Leader in Parotid Gland Cancer
Global Leader in Cervical Adenocarcinoma
Conducts research for Relapse
Conducts research for Breast Cancer
Conducts research for Lung Cancer
397 reported clinical trials
3 medical researchers
Photo of Mercy Hospital Springfield in SpringfieldPhoto of Mercy Hospital Springfield in SpringfieldPhoto of Mercy Hospital Springfield in Springfield

Summary

Mercy Hospital Springfield is a medical facility located in Springfield, Missouri. This center is recognized for care of Parotid Gland Cancer, Cervical Adenocarcinoma, Relapse, Breast Cancer, Lung Cancer and other specialties. Mercy Hospital Springfield is involved with conducting 397 clinical trials across 548 conditions. There are 3 research doctors associated with this hospital, such as Jay W Carlson, Madhu Kalyan Pendurthi, MD, and Sunthosh V. Parvathaneni, MD FHRS FACC.

Area of expertise

1Parotid Gland Cancer
Global Leader
Mercy Hospital Springfield has run 159 trials for Parotid Gland Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Cervical Adenocarcinoma
Global Leader
Mercy Hospital Springfield has run 67 trials for Cervical Adenocarcinoma. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Top PIs

Clinical Trials running at Mercy Hospital Springfield

Esophageal Adenocarcinoma
Lung Cancer
Breast Cancer
Esophageal Carcinoma
Parotid Gland Cancer
Esophageal cancer
Gastroesophageal Junction Adenocarcinoma
Non-Small Cell Lung Cancer
Cancer
Breast cancer
Image of trial facility.

Chemotherapy + Radiotherapy

for Esophageal and Gastric Cancer

This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding radiotherapy to the usual chemotherapy may work better compared to the usual chemotherapy alone in treating patients with esophageal and gastric cancer.
Recruiting2 awards Phase 320 criteria
Image of trial facility.

Proton Therapy vs Photon Radiation

for Esophageal Cancer

This trial studies how well proton beam radiation therapy compared with intensity modulated photon radiotherapy works in treating patients with stage I-IVA esophageal cancer. Proton beam radiation therapy uses a beam of protons (rather than x-rays) to send radiation inside the body to the tumor without damaging much of the healthy tissue around it. Intensity modulated photon radiotherapy uses high-energy x-rays to deliver radiation directly to the tumor without damaging much of the healthy tissue around it. It is not yet known whether proton beam therapy or intensity modulated photon radiotherapy will work better in treating patients with esophageal cancer.
Recruiting2 awards Phase 31 criteria
Image of trial facility.

Chemotherapy + Immunotherapy

for Esophageal and Gastric Cancer

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Mercy Hospital Springfield?
Where is Mercy Hospital Springfield located?
Who should I call to ask about financial aid or insurance network?
What insurance does Mercy Hospital Springfield accept?
What awards or recognition has Mercy Hospital Springfield received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security